Sintetica SA: Harrow Announces U.S. FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

IHEEZO Represents the First Approved Use in the U.S. Ophthalmic Market of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly

Related Keywords

San Diego ,California ,United States ,Canada ,Switzerland ,Mendrisio ,Switzerland General ,American ,Canadian ,Kostenloser Wertpapierhandel ,Jamie Webb ,Markl Baum ,Nicola Caronzolo ,Daniele Fontana ,Deb Holliday ,Exchange Commission ,American Society Of Cataract ,Old International Pharmaceutical Company Sintetica ,Linkedin ,Institute For Safe Medication Practices ,Drug Administration ,Holliday Communications Inc ,First Approved Use ,Chloroprocaine Hydrochloride ,First Branded Ocular Anesthetic Approved ,Canadian Markets From ,Orange Book Listed ,New Drug Application ,Harrow Chairman ,Chief Executive ,Sintetica Chief Executive Officer ,Market Scope ,Safe Medication Practices ,Refractive Surgery ,Full Prescribing ,Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Sintetica ,Arrow ,Nnounces ,Approval ,Heezo ,Hloroprocaine ,Hydrochloride ,Ophthalmic ,Secular ,Surface ,Anesthesia ,